Answers are grounded in this paper and cite their sources.
The renoprotective effects of sodium–glucose cotransporter 2 (SGLT-2) inhibitors, independent of their hypoglycemic actions, have attracted considerable attention in recent years.1–4 Treatment with SGLT-2 inhibitors is accompanied by an acute reduction in the estimated glomerular filtration rate (eGFR), called the initial eGFR "dip," which may result from a decrease in intraglomerular pressure via inhibition of excessive action of tubuloglomerular feedback.5,6 In clinical trials of SGLT-2 inhibitors, the initial eGFR dip was followed by long-term stabilization of kidney-function decline.
No takes yet. Share an insight, caveat, or question.
Shimizu et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: